Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis

dc.creatorFrancesconi, Glaucia
dc.creatorValle, Antonio Carlos Francesconi do
dc.creatorPassos, Sonia Lambert
dc.creatorBarros, Mônica Bastos de Lima
dc.creatorPaes, Rodrigo de Almeida
dc.creatorCuri, André Luiz Land
dc.creatorLiporage, José
dc.creatorPorto, Cássio Ferreira
dc.creatorGutierrez-Galhardo, Maria Clara
dc.date2019-05-30T12:59:49Z
dc.date2019-05-30T12:59:49Z
dc.date2011
dc.date.accessioned2023-09-26T21:02:34Z
dc.date.available2023-09-26T21:02:34Z
dc.identifierFRANCESCONI, Glaucia et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia, v. 171, p. 349-354, 2011.
dc.identifier0301-486X
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/33285
dc.identifier10.1007/s11046-010-9380-8
dc.identifier1573-0832
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8868205
dc.descriptionItraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis. Objective: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Materials and methods: A bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture from all patients (age range: 18–70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits. Results: Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group. Conclusion: Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
dc.description2020-05-30
dc.formatapplication/pdf
dc.languageeng
dc.publisherSpringer Verlag
dc.rightsopen access
dc.subjectSporotrichosis
dc.subjectItraconazole
dc.subjectTerbinafine
dc.subjectTreatment
dc.titleComparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis
dc.typeArticle


Este ítem pertenece a la siguiente institución